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Abstract
Cancer cells undergo several complex processes to grow and evolve. For their 
survival, they manipulate the entire system and acquire the ability to gain all 
the energy demands from the host system itself. Tumor associated macrophages 
(TAMs) are macrophages abundantly present in the tumor micro environment 
(TME) and essentially plays a critical role in coordination with the tumor cells 
helping them to progress and metastasize. One of the key hallmarks in tumor cells is 
elevated metabolic processes such as glycolysis, fatty acid oxidation, mitochondrial 
oxidation, and amino acid metabolism. Macrophages help cancer cells to achieve 
this metabolic demand through a series of signaling events including mTOR, Akt, 
and PI3K pathways. The M2-like phenotype of macrophages leads to the tumor-
ous macrophage phenotype along with the tumor cells to support tumor growth 
through metabolic dysregulation. Focusing upon the area of macrophage-mediated 
tumor metabolism in solid tumors has been a new area that provides new effective 
targets to treat cancer. This chapter discusses the role of macrophages in tumor 
metabolism and cancer progression. Targeting TAMs in tumor microenvironment 
through metabolic axis could be a potential therapeutic option to control the solid 
tumor growth and propagation.
Keywords: macrophages, hypoxia, TME, PD-1, OXPHOS, tumor microenvironment
1. Introduction
The slow pace development of solid tumors inside a human body involves a lot 
of complex process. It is not only the genetic mutations that play important role 
but also the so-called tumor microenvironment (TME), which is a silent player 
enhancing this process. TME has complex players such as the T-cells, dendritic cells, 
and macrophages in the solid tumor [1]. Among these, macrophages have three 
types of classification namely tumor-associated macrophages (TAMs), tissue-
resident macrophages, and myeloid-derived suppressor cells (MDSCs). The most 
abundant tumor infiltrating immune cells in the tumor microenvironment are 
TAMs. These TAMs are classified into two subtypes namely M1 or M2 macrophages. 
Macrophages have a role in defense as well as homeostasis of cells by acquiring 
the capacity of phagocytosis. TAMs have reportedly been associated with several 
functions such as tumor initiation, progression, and metastasis with secretion of 
supporting factors such as cytokines, growth factors, inflammatory substrates, 
and proteolytic enzymes. As macrophages are known to be associated with tumor 
progression, understanding different signaling complexes has been an important 
field. The major signaling molecules involved are cytokines, growth factors, 
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chemokines, and transforming growth factors beta, vascular endothelial growth 
factor, and platelet-derived growth factor. Several murine tumor models have 
reported TAMs as the major source for tumor-promoting factor like IL-6 [2]. The 
VEGF-A factor produced via TAMs specifically helps tumor cells with angiogenesis 
switch providing new blood vessels for tumor progression. TAMs have certain 
immunosuppressive functions apart from their strong inflammatory properties. 
Macrophages are poor producers of IL-12 but highly produce IL-10 and TGF-β with 
the help of STAT-3 activation [3]. The membrane-derived PDL-1 is activated on 
the surface of TAMs by IL-10 and TNF-A. Thus, PDL-1A has a prominent role in 
inhibiting the activated T-effector cells via the PD-1 receptor. TAMs are also widely 
reported to suppress therapeutic conditions such as chemotherapy, irradiation, and 
angiogenic inhibitors.
TAMs are associated with major metabolic changes associated with solid tumor 
progression. Macrophages can have a sudden change in their function while having 
a pathogen attack inside the host. The metabolic network inside a tumor cell has 
been a rich area of study as to decode the signaling molecules and find novel targets 
for the cure of cancer. Glycolysis is one such heavily activated pathway acquired 
by cancer cells to have sufficient energy and other key metabolites to progress and 
survive. TAMs highly elevate the process of glycolysis through HIF-1 stabilization 
and Akt/mTOR pathway [4]. Glycolysis in cancer cells also acts as intermediate for 
other cellular mechanisms such as the pentose phosphate pathway, TCA cycle, lipid 
metabolism, and amino acid metabolism. TAMs are also associated with increased 
OXPHOS despite having abrupt TCA cycle. Together with increased glycolytic flux 
and narrowed pathway of  TCA cycle, OXPHOS promotes the accumulation of 
succinate and citrate in LPS/IFN-Ƴ-activated macrophages. This accumulation of 
succinate leads to a major change in track of pathways by activating the HIF1-alpha 
subunit factor, which is otherwise in normal conditions inactivated by prolyl hydro-
lase enzymatic activity. This enhances production of pyruvate through glycolysis, 
which leads the macrophages to activate inflammatory cytokine production and the 
abrupt TCA cycle enhances the anti-microbial activity. Other metabolic functions 
such as the lipid metabolism are actively supported by the macrophages. These 
macrophages act as a source for synthesizing lipid mediators and fulfill the energy 
requirements in solid tumors. Macrophages utilize glycerides in lipoproteins as their 
major source of free fatty acids. This process is indicated by the increased produc-
tion of lipoprotein lipase (LPL) in activated macrophages. M2-like macrophages 
have shown to have elevated consumption of amino acids in the form of glutamine 
as well as fatty acids [5]. An important mechanism of tumor suppression by mac-
rophages through immunosuppressive phenotype helps solid tumors to evolve 
and grow. This mode of suppressed immunosurveillance in TAMs is mostly led by 
non-saturated fatty acid metabolism in macrophages. Mitochondrial respiration 
takes place with the help of lipid droplets, which regulates the catabolic process 
of free fatty acids (FFAs). mTOR signaling pathway has been reported to play an 
important role in suppressed immunosurveillance of TAMs. The mTORC1 respon-
sibly is involved in the regulation of de novo lipid synthesis with the help of sterol-
responsive element binding protein transcription factors.
Cancer cells and tumor microenvironment has a co-existing phenomenon which 
supports their growth and metastasis. As macrophages are one of the major immune 
cells actively present in the tumor microenvironment, the complex signaling proce-
dure involved between the two is of utmost interest. CSF1 is one such major kind of 
cytokines that comes into play between TAMs and cancer cells to induce an immu-
nosuppressive function to support tumor growth. The CSF-1 induction recruits 
the monocyte-derived macrophages toward the tumor surface and polarizes it to 
a M2-like phenotype, which is coupled to fatty acid oxidation [6]. This leads to the 
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secretion of variety of immunosuppressive factors such as epidermal growth factor 
(EGF). Interestingly, the metabolic influence of TAMs on solid tumors is not unidi-
rectional. Under hypoxia or increased lactate levels, TAMs secrete various cytokines 
associated with metabolic systems such as IL6, TNF, C-C motif chemokine ligand 5 
(CCL5), and CCL18 [7]. These chemokines in particular promote metabolic processes 
like glycolysis as well as key glycolytic enzymes such as hexokinase-II, lactate dehy-
drogenase A (LDH-A), glucose-6-phosphate dehydrogenase etc. One of the major 
factors involved in cancer cells is anaerobic glycolysis or the famous Warburg effect. 
Hypoxia-inducible factor-1A (HIF-1A) is one of the key factors that activates aerobic 
glycolysis and thus stabilizes the long noncoding RNA from lactate-exposed TAMs to 
cancer cells. The main players in the immune system against tumors like the helper 
CD 4+ T-cells, cytotoxic CD 8+ T-cells, and natural killer (NK) cells on activation rely 
on elevated glycolytic metabolism, which in turn supports the tumor cells for their 
energy demands. On a similar note, Treg cells rely majorly on oxidative phosphoryla-
tion for bioenergetic demands. Interestingly this glucose dependency of both tumor 
and immune cells mediates the TAMs to limit the glycolytic flux in effector cells. This 
is mainly done through the expression of CD274, which is also known as PDL-1 and 
is an immunosuppressive molecule. Moreover, PDL-1 is upregulated in cellular types 
like TAMs, endothelial cells, and tumor cells due to the release of interferon gamma 
from effector cells [8]. This interaction delineates the immune effector functions 
and thus balances the metabolic competition majorly toward tumor progression.
Considering the growing knowledge on TAMs and its interaction toward solid 
tumors have given a green signal toward immune-based therapies to treat cancer. 
Majorly focusing on the delineation of M2-like macrophages or their depolarization 
toward M1-like phenotype TAMs. The inhibitor against CSF1R also holds a strong 
promise toward the treatment of such diseases. Strategies to shift the balance from 
M2- to M1-like phenotype macrophages are also being done using inhibitors against 
VEGF-A. Interestingly, considering the factor of co-interaction of TAMs with cancer 
cell and modulating their metabolism provide a great area to identify potential 
targets against these diseases. In line with this notion, inhibitors against MTORC1 
surprisingly favor tumor progression as glycolysis gets inhibited in hypoxia-coupled 
TAMs, which ultimately favors tumor growth. The food and drug administration 
has approved drugs against PDL-1, which is an immune checkpoint blocker, which 
in turn simulates the immune system against cancer cells. In this reference, several 
metabolism-related antibodies can be functioned along with immune stimulators to 
treat certain types of cancer.
2. Macrophages
A sheer claim lead by Elie Metchnikoff stated that in “cellular (phagocytic) 
theory of immunity” the portion of white corpuscle holds an important signifi-
cance in the elements of the immune system as well as protect the individuals 
from the invasion of pathogenic organisms [9]. Furthermore, macrophages show 
key role in immune responses and immunity, also the defensive role assigned to 
them is perfect depiction to execute the phagocytosis of pathogen aggregation. 
These are also held responsible for regulating lymphocyte activation as well as 
proliferation. With the help of antigens and allogenic cells, macrophages play an 
important role in the activation process of T- and B-lymphocytes [10]. Apart from 
these, macrophages also grant defense mechanism against the tumor cells, but 
studies conducted in the past several years describe the mechanism of tumor cell 
killed by macrophages [11]. Tumor-associated macrophages (TAMs) initiate and 
progress human cancers and angiogenesis and are important part of the tumor 
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microenvironment. Targeting TAMs for therapeutic strategy to cure cancer is still 
in doubt [12]. Tumor metastasis is the parent cause of the deaths of cancer patients, 
adding to statement the intrinsic alterations in the tumor cells, but also implicated 
the cross-talk between cancer cells along with their altered components of micro-
environment [12]. Tumor microenvironments (TME) are produced by TAMs, 
which further initiate the immune checkpoint and produce cytokines, chemokines, 
growth factors that are produced in T-cells. By doing this, TAMs have the most 
important functions in facilitating a metastatic cascade of the cancerous cells. At 
the same time, these trigger couple of more targets and few checkpoint blockade 
immunotherapies in order to oppose the tumor progression [13].
The term macrophages is generally defined as large bodies or cells that are 
instituted in the tissues that are present in the stationary forms. These are also 
regarded as the exceedingly multifaceted or the most versatile cells whose func-
tions are based on their basic area of occupancy. Apart from this confinement, 
their pathophysiologic as well as physiologic contexts are considered to be very 
efficient in various studies [14]. Holding this significance in favor of host defense, 
also in primitive organisms, these tend to not only function as the recognition of 
the threats but at the same time engulf along with destroying the threats and in 
the higher organisms, such as humans. Macrophages have important roles in both 
immune responses whether adaptive or innate to the pathogens and also tend to 
serve as the mediators of inflammatory processes [15]. Macrophages are liberated 
as immature monocytes deriving from the bone marrow and further circulate in 
the blood stream in order to finally migrate into the tissues and also undergo the 
final differentiation into the resident macrophages that include kupffer cells in the 
liver, alveolar macrophages in the lung, and osteoclasts in the bone. It is a well-
documented fact that macrophages have immunological and repair functions and 
are the first ones to arrive at the sites of wounding or infection where they carry 
out several functions that are assigned to them [16]. For promoting tissue repair, 
macrophages release proteases, growth factors, and angiogenic factors and for kill-
ing pathogens they release reactive oxygen and nitrogen radicals. They also release 
some chemokines or cytokines to arrange the action and recruitment of other 
immune cells and present the foreign antigens to cytotoxic T-cells [17]. Usually 
they are not lethal to cancer cells until they are triggered, for example, interferon 
gamma (IFN-γ) or lipopolysaccharide (LPS), but once they are triggered, the 
toxicity of cell is directly exerted toward tumor cells or indirectly via the secre-
tion of factors that promote the anti-tumor functions of other cell types; thus, 
macrophages have pro- and anti-inflammatory properties, which depend on the 
signals they receive and the stage of disease they possess, that is the inflammatory 
balance in the microenvironment. Macrophages have multiple phenotypic expres-
sions, which include removal of debris and tissue remodeling, antigen presenta-
tion, regulation of inflammation, target cell cytotoxicity, induction of immunity, 
thrombosis, and various forms of endocytosis [8].
Well promotion comes that of the tumor-associated macrophages (TAMs), 
which cover multiple strands of neoplastic tissues that counts in the angiogenesis 
as well as the vascularization, stroma formation accompanied by dissolution, and 
modulation that supports tumor cell growth which are a part of important enhance-
ment and inhibition. On being activated TAMs are activated, and further gives 
rise to neoplastic cell death covering cytotoxicity and apoptosis, or even evokes 
tumor-destructive reactions led by the alteration of the tumor microvasculature. 
The primary lesions and metastases are known to group of solid tumors that are 
contented with the large numbers of tumor well associated of leukocytes. Famous 
as being the heterogeneous ones in the nature and consisting various as well as 
variable subsets of t-cells which are mainly the helpers, suppressor and cytotoxic, 
5Role of Macrophages in Solid Tumor Metabolism
DOI: http://dx.doi.org/10.5772/intechopen.93182
b-cells, these are considered to be the natural killer (nk) cells, and hence are termed 
macrophages. Significance of these macrophages lies in them making up to 80% of 
the cell mass in breast cancer patients [18]. Due to being heterogeneous in nature, 
macrophages possess wide range of phenotypes like M1 and M2 based on their envi-
ronment stimulation. M1 phenotype is related with active microbe killing and M2 
phenotype is related with tissue remodeling and angiogenesis. When these mono-
cytes come in contact with tumor-derived anti-inflammatory molecules (i.e., IL-4, 
IL-10, prostaglandin E2, and transforming growth factor 1), in tumor cells they 
mature into M2 or polarized macrophages and produce factors that suppress T-cell 
proliferation and activity, possess poor antigen presenting ability, adapt scavenging 
for debris, repairing and remodeling of damaged and wound tissues, and promote 
angiogenesis [19]. In contrast to this, type I or M1 macrophages are immune effector 
cells that kill microorganisms and tumor cells. They present antigens and produce 
high levels of immune stimulatory cytokines. The M2 phenotype appears to be 
that which dominates in tumors, as TAMs show a similar molecular and functional 
profile that is characterized by low expression of differentiation-associated macro-
phage antigens such as carboxypeptidase M and CD51, high constitutive expression 
of interleukin IL-1 and IL-6, and low levels of tumor necrosis factor [20]. Tumor 
cells, endothelial cells, fibroblasts, and macrophages in human tumors expressed 
monocyte chemotactic protein (MCP). MCP and chemokines are TAMs derived 
from monocytes and are recruited largely by CCL2 (chemokine (C–C motif) ligand 
2). MCP-1 highly is expressed in a wide range of tumor types such as meningioma, 
ovarian carcinoma, glioma, and squamous cell carcinoma of uterine cervix and may 
be the main determinant of the macrophages as suggested by some studies. Other 
major chemoattractants like vascular endothelial growth factor (VEGF), CCL3, 
CCL4, CCL5, CCL8, macrophage-colony stimulating factor (M-CSF or CSF-1), 
macrophage migration inhibition factor (MIF), and macrophage inflammatory pro-
tein-1 alpha(MIP-1) are involved in monocyte uptake into tumors and their levels in 
tumor mass often correlate positively with TAM numbers in human tumors [21].
3. Role of macrophage in tumor progression
As it is becoming clear now, the inflammatory cells survive in the tumor micro-
environment and show crucial role in the development of cancer. The best example 
is TAMs that are important components of the mononuclear leukocyte population 
of solid tumors and show an indecisive association with tumors. TAMs exhibit 
several tumorigenesis-promoting functions, which have significant roles in the 
growth and progression of cancer such as these tend to qualify in providing the 
cytokines and also when it comes to induce tumor angiogenesis [22]. TAMs produce 
many types of protein digestive enzymes, growth factors, inflammatory mediators, 
and cytokines in tumor microenvironment that are the main factors in the metasta-
sis of cancer cells. Not only this, TAMs’ function and movement are also regulated 
in tumor microenvironment by cytokines and hypoxia. Some studies suggest that 
TAMs come in contact with cancer cells, they alter ECM and promote invasion and 
metastasis of cancer cell and several studies show the release of natural products 
by TAMs to inhibit the formation of pro-inflammatory cytokines and growth 
factors and also correlation with cancer metastasis and poor prognosis in various 
types of cancers that happen in humans [23]. The tumor in various murine models 
shows IL-6 (tumor-promoting) as the main source of TAMs, and also that the 
tumor-related myeloid cell production of IL-6 promotes proliferation in colon cells 
along with the apoptosis prevention through STAT3 activation. There is a Doppler 
effect observed in pancreatic cancer, IL-6 derived from myeloid cell initiate tumor 
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development possess from epithelial precursor lesions through STAT3 [16]. In a 
specific genetic model of colorectal cancer, initiation of tumor starts with the loss 
of the adenomatous polyposis coli tumor suppressor gene, which results in the 
activation of β-catenin and further causes the barrier disruption of the epithelium. 
It allows the products of microbes to penetrate and moreover causes IL-23 macro-
phage production. In CD4+ T-cells, IL-23 drives Th17 response through IL-6 and 
IL-17, which initiate colorectal cancer [24].
The proportion of blood capillaries present in the non-infectious tissues mainly 
rests in an inactivated state in which angiogenesis transiently gets started in the per-
fect response in favor of certain stimuli. On the contrary, at the time of tumor initia-
tion, an “angiogenic switch” is almost always initiated as well as turned on, which 
leads to vascularization of new capillaries from the inactivated state. On comparing 
the normal vascular network, the network of blood capillaries that are present in the 
tumors are basically identified by the complex and excessive branching of the blood 
vessels, which are contorted and also become large vessels, show irregular blood 
flow, microhemorrhage, and leakiness [25]. Macrophages are very particular to 
switch this angiogenic, that in the case of tumors mainly goes through production of 
vascular-endothelial growth factor A (VEGF-A) along with placental growth factor 
(PlGF). Talking of the specificity the blood vessels present in the tumors lacking 
myeloid cell-derived VEGF-A were less tortuous then having more pericyte cover-
age as well as the less vessel length. Above mentioned characteristics are consider 
successfully that show normal blood vessels. These are further counted upon 
modifying the bioavailability of VEGF-A in the tumors by matrix metalloproteinases 
processing. Adding to this fact, antibody-mediated neutralization of angiopoietin 2, 
the ligand for the Tie2 receptor, or macrophage depletion blocks tumor angiogenesis 
as well as limits tumor progression in a mouse model of breast cancer [26]. Several 
studies conducted on the patients having cancer in liver cells showed that the mar-
ginal macrophage density is different from the macrophage density present inside 
the tumor of the liver although they are directly associated along with the vascular 
invasion, tumor multiplicity, and also fibrous capsule formation. Furthermore, 
there was an important relationship observed between the density of TAMs as well 
as in the poor prognosis in those patients. According to Hansen et al., CD64+ macro-
phages (TAMs) are present in high numbers in tumor biopsies before treatment and 
thus show a negative relation along with clinical outcomes in the patients with the 
metastatic melanoma who undergo IL-2 based immunotherapy [27].
4. Tumor microenvironment
Tumor microenvironment (TME) changes continuously during the tumor 
development in parallel with the tumor growth. These changes on the one hand 
influence the immune cells’ function and the complex relationship between 
tumor cells and these cells, and on the other hand influence its cellular content 
through the release of several factors, which leads to the accumulation of specific 
types of immune cells into the TME. Hypoxia and limitation of blood-borne 
nutrients are a characteristic feature of TME, while being enriched in reac-
tive nitrogen species (RNS), protons, and other by-products released from 
the activated tumor cell metabolism [28, 29]. It is therefore important for the 
tumor cells to acclimatize their metabolism in order to survive in oxygen- and 
nutrients-deprived TME, and to respond to their increased demands of energy 
depending on their enhanced proliferation rate. The metabolic changes have been 
described over a century ago as “Warburg phenomenon” or “aerobic glycolysis,” 
where tumor cells exploit glycolysis in order to provide energy regardless of the 
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availability of oxygen [30]. Under hypoxic conditions, the cellular metabolism 
migrates toward anaerobic glycolysis to generate energy, rather than oxidative 
phosphorylation (OXPHOS), which plays a major role in terms of adenosine 
triphosphate (ATP) production [31]. As a consequence of the increased rate of 
glycolysis, the pyruvate is significantly reduced to lactate. This causes upregu-
lated lactate levels that are released in TME by monocarboxylate transporters 
(MCTs) and that results in reduction in the pH levels and local acidification, 
while pH within the tumor remains normal [32]. In TME, this significant reduc-
tion in the pH levels causes cytotoxic environment for cells, including immune 
cells such as macrophages that are activated and recruited to restrict the progres-
sion of tumor and eliminate the tumor. This provides survival benefit to the 
cancer cells [29]. Additionally, the toxic waste, for example, lactic acid has been 
shown to frame and shape the functional phenotype of recruited macrophages 
toward more tolerogenic phenotypes and conferring them with proangiogenic 
and pro-tumorigenic properties [33].
5. Metabolic reprogramming of TAMs
TAMs are involved in multiple processes, which result in the promotion and 
progression of primary tumor facilitating metastasis. The compartment of TAM 
via an extensive remodeling of energy metabolism evolves over time (i.e., during 
treatment response and tumor progression) as well as in space (at various tumor 
sites) [34]. The variations in TAMs in response to the nutritional needs of solid 
tumor are very dynamic and TME perturbations have a major influence not only on 
the survival of TAM but also on tumor progression [35] (Figure 1).
5.1 Glucose metabolism in macrophages
TAMs majorly support the progression of tumor by (i) indirectly enhancing 
the nutrients’ availability in the TME, (ii) providing signals to tumor cells, and 
(iii) mediating immunosuppressive functions. “Neoangiogenesis” is the major 
Figure 1. 
TAM compartment is highly polarized toward M1-like state. Tumor progression depletes TME for the 
availability of glucose since it produces significant amount of lactate and polarization toward M2-like state. 
M2-like TAMs show restricted activity of phagocytes, chemokine, and cytokine secretion that facilitates 
the neoangiogenesis process, deprive TME of amino acids such as glutamine for T-cell function supporting 
remodulation of ECM. This metabolic alteration results in tumor growth and progression. (TAM: Tumor-
associated macrophages; TME: Tumor microenvironment; ECM: Extracellular matrix).
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mechanism of nutritional support to the solid tumor cells by products derived 
from TAM such as adrenomedullin (AMD), C-X-C motif chemokine ligand 8 
(CXCL8), vascular endothelial growth factor A (VEGFA), and CXCL12 [36, 37]. 
Although the vasculature of tumor is functionally and phenotypically impaired, 
neoangiogenesis plays a crucial role for the growth of neoplasms in this scenario 
[38]. TME has been shown to exhibit some degree of hypoxia, which facilitates 
TAMs’ tumor-supporting functions majorly via two mechanisms: First, hypoxic 
condition supports the upregulation of lipocalin 2 (LCN2), and upregulation of 
solute carrier family 40 member 1 (SLC40A1 or FPN). This causes the acquisition 
of an iron donor phenotype by TAMs, therefore enhanced availability of iron in the 
TME, and thus improved iron uptake by malignant cells and significant prolifera-
tion [39]. Wenes et al. investigated the character of metabolically activated hypoxic 
macrophage in metastasis and the blood vessel morphogenesis. It was observed 
that hypoxia causes TAMs to upregulate REDD1 (regulated in development and 
in DNA damage response 1), which causes the inhibition of mTOR, and further 
glycolysis inhibition. This was linked with an enhanced response to angiogenesis 
and leaky vessels formation. As a consequence, hypoxic TAMs migrate toward 
oxidative mode of metabolism coupled with decreased intake of glucose, which 
causes hyperactivation of endothelial cells and results in metastasis and neoangio-
genesis because of the increased availability of glucose in the TME. However, the 
physiological relevance of such shift in humans has not been proven yet [40]. Under 
normoxia, TAMs exhibit downregulated activity of succinate dehydrogenase (SDH) 
and lower glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as compared to 
normal macrophages, aiding their potential to function on relatively low inputs of 
nutrients as found in the TME. Interestingly, the activity of GAPDH was observed to 
be more downregulated in M2-like than M1-like macrophages infiltrating colorectal 
tumors in humans [41]. In a similar manner, in human gliomas TAMs derived from 
monocytes showed reduced glucose metabolism than tissue-resident TAMs, which 
was linked with poor patient survival and escalated immunosuppression in the 
TME. These observations in TAMs suggest that decreased glycolytic activity elicits 
progression of tumor via both immunosuppression and nutritional circuitries [42]. 
Even when a decreased glycolysis metabolism in TAMs spears to favor growth of the 
tumor in a majority of settings, tissue section analysis and co-culture experiments in 
TAMs showed that production of lactate by human medullary carcinoma cells causes 
a shift from OXPHOS to glycolysis, couples to upregulated secretion of interleukin 
6 (IL6), lactate and tumor necrosis factor (TNF), ultimately supporting tumor pro-
gression [43]. Additionally, proteomic analysis demonstrated that enzymes involved 
in glycolysis such as hexokinase 2 (HK-II) are increased in TAMs from individuals 
with pancreatic cancer and macrophages derived from bone marrow exposed to 
breast carcinoma extracts from individuals suggesting an enhanced rather than 
decreased capacity in glycolysis [44, 45]. Therefore, glycolysis in TAMs can facilitate 
tumor progression and growth irrespective of an increased competition for local 
availability of glucose [44].
Macrophages-mediated metabolic reprogramming in tumor is not only limited 
to glycolysis. Through the different glycolysis intermediates, glycolysis is directly 
associated with various other intracellular metabolic pathways. This includes fatty 
acid (FA) and glutamine metabolism, pentose phosphate pathway (PPP), and 
amino acid metabolism.
5.2 Fatty acid and glutamine metabolism
M2-like TAMs also display increased consumption of fatty acid and glutamine. 
The latter represents relatively increased levels of metabolic enzymes and glutamine 
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transporters expression, observed in both in vitro and in vivo in primary human 
TAMs [43]. In line with this, another study shows, glutamate ammonia ligase 
(GLUL) facilitates polarization of M2 by catalytic conversion of glutamate to 
glutamine, at least in vitro [46]. Therefore, inhibition of GLUL supports the M2-like 
TAMs repolarization into M1 counterparts along with enhanced flux of glycolysis 
and availability of succinate, suggesting the role of glutamine metabolism in TAMs 
regulation. Also, depletion of glutamine restrains polarization of M2-like macro-
phages in murine as a result of limited availability of a-ketoglutarate for epigenetic 
reprogramming [47]. A similar outcome ensues N-glycosylation inhibition sug-
gesting the limited synthesis of aspartate-dependent UDP-N-acetyl-glucosamine 
(UDP-GlcNac) [47] and limited glucose-acetyl-CoA, which also plays a crucial role 
in epigenetic functions [48]. The former is the result of interleukin 4 (IL4)-driven 
activation of signal transducer and PPARG coactivator 1 beta (PPARGC1B), lead-
ing to enhanced epigenetic reprogramming and mitochondrial biogenesis toward 
fatty acid oxidation (FAO) [49]. Therefore, inhibition of pharmacological FAO 
reportedly supports repolarization of M1-like and M2-like macrophages [50], 
while upregulation of fatty acid synthase (FASN) in several subsets of TAM has 
been shown to favor pulmonary tumorigenesis because of the secretion of colony 
stimulating factor 1 (CSF1). In such a setting, TAMs have shown to support tumor 
progression by immunosuppressive cytokine interleukin 10 (IL10) release down-
stream of peroxisome proliferator-activated receptor delta (PPARD) [50]. The latter 
observation suggests the crosstalk between immune and metabolic functions in 
the TME. Some TAMs accumulate intracellular source of lipids in order to support 
metabolic fitness in tumor [51]. This suggests the alteration in majority of crucial 
factors involved in lipid metabolism such as monoglyceride lipase (MGLL), abhy-
drolase domain containing 5 (ABHD5), and acyl-CoA dehydrogenase medium chain 
(ACADM) [51–53]. Therefore, these observations suggest the major role of TAM 
metabolism on their ability to influence tumor progression and growth.
5.3 Amino acid metabolism
TAMs, exclusively pro-tumorigenic and M2-like macrophages, exhibit increased 
utilization of glutamine. This is linked with upregulated levels of intermediates 
such as uridine diphosphate N-acetylglucosamine, which are needed for N linked 
glycosylation of M2-like macrophages-associated receptors. Consequently, inhibiting 
the process of N-glycosylation and glutamine deprivation impairs polarization of 
M2-like macrophages along with downregulation in the TCA cycle [47]. Additionally, 
TAM isolated and exposed to glioblastoma cell lines exhibited enhanced gene expres-
sion related to metabolism [54]. The metabolism of L-arginine has also been shown 
to be associated with TAMs function. L-arginine can be used either through arginase 
metabolic pathway or for the synthesis of NO in macrophages. NO synthesis path-
way is the characteristic feature of M1-like macrophages. Arginine is converted to 
L-citrulline and NO by nitric oxide synthase (iNOS). The NO furthermore down-
regulates OXPHOS through inhibition of electron transport chain (ETC) and TCA 
cycle enzymes and increases glycolysis [55, 56]. While on the other hand, expression 
of arginase (ARG1), enzyme that plays a crucial role in urea cycle, is the characteris-
tic feature of M2-like macrophage, which hydrolyses arginine to urea and ornithine 
and restricts the availability of arginine for NO synthesis [57, 58]. TAM isolated from 
human ovarian and murine mammary tumors showed reduced cytotoxic properties 
linked with a decreased production of NO and a lower expression of iNOS in tumor-
bearing mice [59, 60]. Another study demonstrated elevated expression of Arg1 in 
TAMs isolated from murine models. Lactate and hypoxia have been studied to be 
able to upregulate Arg1 expression [13]. Colegio et al. in lung cancer murine model 
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demonstrated that Arg1fl/fl X Lysmcre/wt mice, with deficient ARG1 in macro-
phages, developed small-sized tumor as compared to the wild-type mice [33]. In 
the same study, TAMs exhibited upregulated expression of urea cycle. Additionally, 
metabolites such as tryptophan and cysteine derived from L-arginine are crucial 
mediators of myeloid-derived suppressor cells (MDSC). These findings highlight the 
role of nitrogen cycle in TAMs’ function [61].
6. Signaling cross-talk between macrophages and solid tumor
Colony stimulating factor 1 (CSF1), the major cytokine, plays an important role 
in the interplay between TAMs and tumor cells [62]. After binding to its cognate 
receptor, CSF1 facilitates monocyte-derived macrophages’ recruitment to tumor bed 
and M2-like macrophages polarization. This is accompanied with (1) upregulation 
of FAO [63] and (2) immunosuppressive and pro-tumorigenic factor secretion, such 
as IL10 [64] and epidermal growth factor (EGF) [65]. Accordingly, inhibition of 
colony stimulating factor 1 receptor (CSF1R) with monoclonal antibodies or small 
molecules supports the M1-like TAMs’ accumulation [66]. This is accompanied by 
glycolysis restoration, mediating therapeutic effects in majority of tumor models. 
CSF1, VEGFA, and IL34 supporting TAMs’ growth is sensitive to chemotherapeutic 
environmental stress, local pH, nutrient availability, and oxygen tension [33, 62]. 
Therefore, metabolism of lactate is exclusively relevant not only for metabolic symbi-
osis between normoxic and hypoxic cancer cells but also for the potential of hypoxic 
cancer cells to decrease TAMs toward poor M2-like glycolytic profile, exhibiting 
upregulation of FAO, reduced potential for antigen presentation [67]. Additionally, 
M2 polarization of TAMs-associated melanoma is elicited by a G-protein-coupled 
receptor (GPCR) signaling mechanism that senses acidification of TME induced 
by increased glycolysis in cancer cells [68]. Mathematical modeling accompanied 
with in vivo experiments revealed the potential of TAMs to support the process of 
neoangiogenesis. This specific metabolic alteration has additional immunological 
consequences, as VEGFA favors the immunosuppressive receptors’ expression [69]. 
Upregulated activity of lactate in the TME causing hypoxic nature contributes to 
the arginine catabolism by arginase 1 (ARG1) and ARG2 over nitric oxide synthase 2 
(NOS2), causing enhanced secretion of factors supporting tumor such as polyamines 
and ornithine by TAMs [33, 69]. The levels of ARG1 can be increased in M2-like 
TAMs by signals induced by apoptotic cancer cells [70], such as FASN-dependent 
pathway driven by CSF1 [42] and sphingosine-1-phosphate (S1P). Also, lactate 
contributes polarization of M2-like macrophages in murine breast cancer models 
by triggering G-protein-coupled receptor 132 (GPR132) signaling. Accordingly, 
upregulated levels of GPR132 elicit infiltration in breast cancer by monocyte-derived 
macrophages, which certainly acquire functions supporting tumor phenotype. 
Another receptor of lactate, hydroxycarboxylic acid receptor 1 (HCAR1), seems to be 
upregulated in M1-like TAMs [71]. Additionally, cancer cells’ metabolic influence on 
TAMs is not unidirectional. Therefore, when TAMs are exposed to the hypoxic condi-
tions or upregulated lactate levels, they secrete variety of cytokines such as TNF, 
IL6, C-C motif chemokine ligand 5 (CCL5), and CCL18 [72]. IL6 supports glucose 
metabolism by mediating 3-phosphoinositide-dependent protein kinase 1 (PDPK1) 
potential to phosphorylate CCL5, TNF, phosphoglycerate kinase 1 (PGK), and CCL18 
enhances pro-glycolytic factors such as PGK1, HXK2, glucose-6-phosphate dehydro-
genase (G6PD), lactate dehydrogenase A (LDHA), vascular cell adhesion molecule 
1 (VCAM1), pyruvate dehydrogenase (PDH), pyruvate dehydrogenase kinase 1 
(PDK1), and GLUT1 [73]. Apart from these findings, Warburg phenomenon is 
triggered, both in vitro and in vivo, by transfer of long noncoding RNA of hypoxia 
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inducible factor 1 subunit alpha (HIF1A) from TAMs exposed to lactate to the tumor 
cells. Intriguingly, HIF1A have been shown to play a crucial role in exacerbating 
tumor glycolysis as well as M2 polarization. Furthermore, M2-like TAMs trigger 
hypoxia in an active manner [37] (Figure 2).
7.  Therapeutic strategies against macrophages-mediated tumor 
metabolism
As now it is very evident that TAMs and tumors have very complex interactions 
between them, which supports the tumor progression, growth, and metastasis, 
researches across the globe are widely studying this area and finding novel targets 
against the immune regulators and metabolic mediators in the system. TAMs are the 
widely found immune cells in the tumor microenvironment and undergo complex 
processes to support the tumor growth. M2-like TAM phenotype is highly reported 
from studies to likely support the tumor progression. This conclusion supports the 
idea of developing antibodies that intervene with the M2 phenotype macrophage 
function. CCL2 blocking agents have been a promising antibody against cancer 
metastasis and cancer death. Therefore, strategies to deplete the M2 phenotype into 
non-tumorous M1 phenotype have been a promising step toward treating cancer. 
Drugs associated with metabolic blockers also paved a new method for treating 
cancer. Drugs such as inhibiting HK-II helped in the inhibition of pro-metastatic M2 
phenotype of TAMs. Similarly, drugs inhibiting FAO also appear to be a promising 
field to target pro-tumoral macrophage as well as tumor metabolism. T-cells are the 
major players contributing toward immune-mediated cell metabolism, which is 
also approached as an effective target. PD-1 ligation with T-cells helps in the shift 
in metabolism from glycolysis to FAO, which maintains the longevity of T-cells and 
impairs their effector function (Table 1).
Figure 2. 
Metabolic cross-talk signatures between TAMs and cancer cells. As cancer cells begin to proliferate in an 
uncontrollable manner, they start consuming elevated levels of glucose and other biosynthetic products to 
progress. This triggers the release of CSF-1 into the tumor microenvironment, which repolarizes the M1-like 
phenotype macrophages into M2-like macrophages. The M2-like state then releases several chemokines such as 
EGF, CCL-5, CCL-18, which act as immunosuppressive molecules. The expensive use of lactate by cancer cells 
delineates the immune function of T effector cells. Moreover, M2-like macrophages upregulated mitochondrial 
phosphorylation and fatty acid oxidation.
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Therefore, strategies that target macrophages along with tumor metabolism 
without encouraging the tumor cell growth have been quite challenging and have 
provide an effective means to treat the solid tumors.
8. Conclusion
Solid tumors are evolving over the years strongly by acquiring the capability 
to manipulate the host system to help them attain energy demands to survive and 
metastasize. One such player helping tumor cells is the macrophages. The polariza-
tion of macrophages into tumorous M2 phenotype helps the cancer cells in their 
glycolytic demands. Metabolic events such as amino acid metabolism and oxidative 
phosphorylation are triggered in cancer cells. The hypoxia event in cancer cells 
stimulates the signaling events toward glycolysis increasing glycolytic enzymes such 
as hexokinase-II, LDH-A, and pyruvate dehydrogenase. Thus, series of research has 
proved that macrophages has an important role to play in tumor metabolism inside 
the TME. This kind of immunometabolism has triggered challenges and interest in 
finding novel targets on this area to cure the disease cancer.
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